ZUG, Switzerland, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Auris Medical Holding AG announced today the pricing of its initial public offering of 9,400,000 of its common shares at an initial public offering price of USD 6.00 per common share. In addition, Auris Medical has granted the underwriters an option to purchase up to 1,410,000 additional common shares at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the initial public offering are expected to be approximately USD 51 million. The offering is expected to close on or about August 11, 2014, subject to customary closing conditions. Auris Medical's common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol "EARS" on August 6, 2014.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers in the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers in the proposed offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission ("SEC") on August 5, 2014. The offering is being made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by emailing Prospectus_Department@Jefferies.com, or by calling (877) 547-6340 or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by email at firstname.lastname@example.org, or by calling (800) 808-7525.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.
Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94,
Source: Auris Medical AG